Obinutuzumab (anti-CD20)

Catalog No.A2023        Batch: A202301

Print

Technical Data

CAS No. 949142-50-1
Formulation PBS buffer, pH 7.2
Isotype Human IgG1 isotype control
Source Humanized (from mouse)
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99.65%
Protein concentration 5 mg/ml
Endotoxin Level ≤1 EU/mg

Biological Activity

Description Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.
In vitro

GA101 is the first Fc-engineered, type II humanized IgG1 antibody against CD20. Relative to rituximab, GA101 has increased direct and immune effector cell-mediated cytotoxicity and exhibits superior activity in cellular assays and whole blood B-cell depletion assays.[3]
In vivo

In human lymphoma xenograft models, GA101 exhibits superior antitumor activity, resulting in the induction of complete tumor remission and increased overall survival. In nonhuman primates, GA101 demonstrates superior B cell–depleting activity in lymphoid tissue, including in lymph nodes and spleen.[3]

Protocol (Only for Reference)

Cell Assay:

  • Objective: Annexin V/PI FACS assay
    Cells: NHL cell lines
    Concentrations: 10 μg/mL
    Incubation Time: 36 hr
    Method: For CD40 stimulation of hCD20 cells from transgenic mice, red blood cells (RBCs) are removed by hypotonic ammonium-chloride-potassium (ACK) lysis, and untouched splenic B cells are purified by anti-CD43–mediated depletion of non-B cells (MACS). B cells are incubated in conditioned complete RPMI 1640 medium containing 10% fetal bovine serum for 2 hours (with or without 10 μg/mL mitogenic stimulation) and either anti-CD40 or anti-IgM Fab2 antibodies. This is followed by 36 hours of anti-CD20 stimulation (GA101 or rituximab 10 μg/mL). As positive controls for the induction of cell death, the following agents are used: 100nM staurosporine for mitochondrial-mediated apoptosis, or 1 μg/mL anti-CD95 Fas for the extrinsic induction of apoptosis.
    Reference: https://pubmed.ncbi.nlm.nih.gov/20194898/

    Obinutuzumab can apply to humanized mice (eg:SCID beige mice), peripheral blood and other related assays (Only for Reference)
Animal Study:

  • Objective: Tumor control ratio (TCR) and tumor growth inhibition (TGI)
    Animal Models: 4- to 8-week-old female SCID beige mice
    Formulation: --
    Dosages: 30 mg/kg
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/24304419/

    Objective: NHL xenograft studies in SCID beige mice
    Animal Models: 4 to 5-week-old female SCID beige mice
    Formulation: --
    Dosages: 10 mg/kg, 30 mg/kg
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/20194898/

    Obinutuzumab can apply to humanized mice (eg:SCID beige mice), peripheral blood and other related assays (Only for Reference)

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.